All authorized agents for medicine are hereby informed that all new products will need Bio availability/ Bio equivalence data for full registration with effect from 26.02.2021.

For BCS class I and class III products that have WHO bio waiver monographs, comparative dissolution data are accepted.

CEO

NMRA

(Date: 15 March 2021)